Saturday, May 01, 2021 9:23:16 PM
I agree that there was little interest in the prepare it presentation in February and there was also very little interest in the cardioLink-9 trial in Toronto in December. Things have changed. In February they announced that of the 1500 patients who were high risk healthcare professionals or family members of Covid positive patients that only 8% tested positive after two months. This was blinded data of both groups. At the time it was thought there was prepare-it 2 with an additional 500 patients who were Covid positive ambulatory outpatients. It now appears that both prepare-it one and prepare-it 2 each have 2000 patients in each trial. The Toronto trial was a phase 2 biomarker trial which had very encouraging data but only 100 pts. Argentina is running a trial of 2000 such patients. The data from these 4000 patients (combined) will give strong data (neutral or positive). IMHO the chances of stat sig efficacy in reducing the severity and duration of COVID are good. I have studied the pharmacology more intensely than any other topic in my life. The science seems very encouraging. I have had several Pt’s put on V as well as myself and the benefits have been obvious. The pathology of Covid is becoming more clear and everything pointing to an imbalance in the immune system with the inflammatory process spiralling out of control. Vascepa appears to restore balance to the immune system and reduce the exaggerated inflammatory response. There have been a couple positive Colchicine Trials recently and they have a similar mechanism of action in reducing the inflammatory response. The same people running the Argentina trial just completed a large colchicine trial and they certainly appeared to be celebrating (awaiting publication of results). Prepare-it 1 was for prevention of infection. Prepare-it 2 was to reduce the severity and duration of Covid positive outpatients. Colchicine was for inpatient severely ill. Three different patient populations and so positive Colchicine results will not wreck positive Vascepa results. If results are positive there will be supply problems. Also, positive Covid results SUGGEST it would work in other illnesses as well such as influenza, sepsis and other inflammatory conditions.
Here is a link to a document where I try and explain the science. https://docs.google.com/file/d/13dd7yIWqfdk0FlwUKRH32DJs3zAhe8zh/edit?usp=docslist_api&filetype=msword
Here is a short video where I explain with audio : https://drive.google.com/file/d/1EzskElGTt12lxXBudlgDF3SVWoB9R9pb/view?usp=drivesdk
Recent AMRN News
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM